| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 08/22/2002 | WO2002064741A2 Compositions and methods relating to breast specific genes and proteins |
| 08/22/2002 | WO2002064737A2 Antisense modulation of protein phosphatase 2 catalytic subunit beta expression |
| 08/22/2002 | WO2002064732A2 POLYNUCLEOTIDE ENCODING A NOVEL HUMAN POTASSIUM CHANNEL ALPHA-SUBUNIT, K+alphaM1, AND VARIANTS THEREOF |
| 08/22/2002 | WO2002064625A1 Matrix gene expression in chondrogenesis |
| 08/22/2002 | WO2002064621A2 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
| 08/22/2002 | WO2002064612A2 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/22/2002 | WO2002064172A2 Fhit gene therapy prevents tumor development in fhit-deficient mice |
| 08/22/2002 | WO2002064171A1 Adenoviral transduction of fragile histidine triad (fhit) into cancer cells |
| 08/22/2002 | WO2002064169A1 Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases |
| 08/22/2002 | WO2002064164A1 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same |
| 08/22/2002 | WO2002064161A2 Method and compositions for immunization with the pseudomonas v antigen |
| 08/22/2002 | WO2002064157A2 Localized myocardial injection method for treating ischemic myocardium |
| 08/22/2002 | WO2002064156A1 Selective killing of rapidly dividing cells |
| 08/22/2002 | WO2002064021A2 Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity |
| 08/22/2002 | WO2002045652A3 Tyrosine kinase inhibitors |
| 08/22/2002 | WO2002036170A3 Vector system for transducing the positive neurons |
| 08/22/2002 | WO2002000689A3 HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR11, AND USES THEREOF |
| 08/22/2002 | WO2001092330A3 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation |
| 08/22/2002 | WO2001083553A3 G protein-coupled receptors |
| 08/22/2002 | WO2001074903A3 Cd20/ige-receptor like molecules and uses thereof |
| 08/22/2002 | WO2001072295A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/22/2002 | WO2001070982A3 Brca-1 regulators and methods of use |
| 08/22/2002 | WO2001042506A9 T1 receptor-like ligand ii and uses thereof |
| 08/22/2002 | WO2000038706A9 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 08/22/2002 | WO2000026247A9 Ikaros isoforms and mutants |
| 08/22/2002 | WO2000011195A9 C-myc is activated by beta-catenin and tcf-4 |
| 08/22/2002 | WO1999058143A9 Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
| 08/22/2002 | US20020116724 Nucleotide sequences codingolypeptide for use in the diagnosis and prevention of psoriasis and venous ulcers |
| 08/22/2002 | US20020115844 Novel human lipase and polynucleotides encoding the same |
| 08/22/2002 | US20020115716 Oral low dose butyrate compositions |
| 08/22/2002 | US20020115633 Isolated polypeptide with an ability of the Y353 ezrin mutant to induce apoptosis having an amino acid sequence of the Y353 ezrin mutant and also having >7 contiguous amino acids (350-356); antitumor agents |
| 08/22/2002 | US20020115631 Human bad polypeptides, encoding nucleic acids and methods of use |
| 08/22/2002 | US20020115630 Isolated nucleic acids molecules, designated 33449 nucleic acid molecules, which encode novel protease or S26 signal peptidase family members. Antitumor, -carcinogenic and -proliferative agents; kits |
| 08/22/2002 | US20020115627 Phosphatonin-related gene and methods of use thereof |
| 08/22/2002 | US20020115626 Comparing the expression of the nucleic acid encoding an antileuko-protease polypeptide of a cell population to the expression of a nucleic acid encoding the same peptide in an inflammation positive reference profile; enzyme inhibitors |
| 08/22/2002 | US20020115625 Administering an immunogenically effective amount of nucleic acid encoding one or more relevant epitopes of one or more desired target antigens to initiate a cellular (including the induction of cytotoxic T lymphcytes) and humoral response |
| 08/22/2002 | US20020115612 High-speed automated solid-phase synthesis repeating steps of acylation of a resin-bound secondary amine with haloacetic acid followed by nucleophilic displacement of the halogen by an N-substituted amine; libraries |
| 08/22/2002 | US20020115608 Uses of transgenic animals containing a type X collagen mutant |
| 08/22/2002 | US20020115604 HCaRG, a novel calcium-regulated gene coding for a nuclear protein |
| 08/22/2002 | US20020115599 Nucleic acid of given sequence; protein involved in mechanisms during mitosis |
| 08/22/2002 | US20020115598 Method for the improvement of neuronal regeneration |
| 08/22/2002 | US20020115595 Bioactive agent is covalently conjugated to an organocobalt complex's cobalt atom through a non-reactive atom in the bioactive agent molecule such as peptide, protein, nucleic acid and analogues |
| 08/22/2002 | US20020115218 Gene delivery vectors with cell type specificity for primary human chondrocytes |
| 08/22/2002 | US20020115214 Induction of lymphocytes; obtain cells, activate cells, incubate with activator, monitor lymphocyte proliferation |
| 08/22/2002 | US20020115207 Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| 08/22/2002 | US20020115206 Established cell line of microglia |
| 08/22/2002 | US20020115202 Adenoviral vectors including dna sequences encoding angiogenic inhibitors |
| 08/22/2002 | US20020115188 Genetically engineered baculovirus for use as a tool in gene therapy |
| 08/22/2002 | US20020115187 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of arthritis and cancer; for use as antiscarring agent |
| 08/22/2002 | US20020115183 Enzymatic protien for us ein prevention of tumor metastasis |
| 08/22/2002 | US20020115177 Regulation of human histone deacetylase |
| 08/22/2002 | US20020115176 Polypeptide for use in the diagnosis and treatment of asthma, and respiratory disorders |
| 08/22/2002 | US20020115167 Isolation of drosophila and human polynucleotides encoding PAR-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 08/22/2002 | US20020115156 Connective tissue growth factor for use in the treatment of cancer, fibrotic defects and atherosclerosis; for use as wound healing agents |
| 08/22/2002 | US20020115150 Polypeptide for use in the treatment and diagnosis of vision defects and diabetes |
| 08/22/2002 | US20020115149 Nucleotide sequences coding membrane protein for use in the treatment of Parkinson's disease, eating disorders, tension and headaches |
| 08/22/2002 | US20020115140 Nucleotide sequences coding preferential polypeptide for use in treatment of immmunological defects |
| 08/22/2002 | US20020115138 Nucleotide sequences coding transport protein for use in treat ment of tumors |
| 08/22/2002 | US20020115120 Controlling polypetide activity in cell; obtain cell, incubate with modulator, monitor gene expression and protein activity |
| 08/22/2002 | US20020115102 Novel protein |
| 08/22/2002 | US20020115090 Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 08/22/2002 | US20020115081 Nucleotide sequences coding polypeptide for use in the the treatament of cardiovasculAR disorders |
| 08/22/2002 | US20020114811 Contacting body fluid from mammal with antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form antigen-antibody complex and detecting complex |
| 08/22/2002 | US20020114810 Diagnosis and treatment of malignant neoplasms statement as to federally sponsored research |
| 08/22/2002 | US20020114803 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 08/22/2002 | US20020114797 Composition and methods for modulating the length of telomeres |
| 08/22/2002 | US20020114792 Alpha-2-macroglobulin therapies and drug screening methods for Alzheimer's disease |
| 08/22/2002 | US20020114789 Methods of controlling proliferation and differentiation of stem and progenitor cells |
| 08/22/2002 | US20020114787 Tolerance to natural antibody antigens |
| 08/22/2002 | US20020114783 Human gene therapy for inherited or acquired proliferative ocular disease; transduction of mitotically active and inactive cells |
| 08/22/2002 | US20020114772 Methods of modulating hair growth |
| 08/22/2002 | DE10104584A1 Medane-Gene und- Proteine Medane genes and- proteins |
| 08/22/2002 | DE10100238A1 Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests A method for predicting the risk potential for cancer diseases and inflammatory bowel disease and related tests |
| 08/22/2002 | CA2856986A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | CA2854685A1 Optimized messenger rna |
| 08/22/2002 | CA2440743A1 Matrix gene expression in chondrogenesis |
| 08/22/2002 | CA2439129A1 Novel cellular adhesion molecule of activated leukocyte |
| 08/22/2002 | CA2438658A1 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
| 08/22/2002 | CA2438590A1 Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1 |
| 08/22/2002 | CA2438501A1 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | CA2438420A1 Amplified cancer gene wip1 |
| 08/22/2002 | CA2438153A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | CA2438125A1 Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof |
| 08/22/2002 | CA2437811A1 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/22/2002 | CA2433936A1 Localized myocardial injection method for treating ischemic myocardium |
| 08/22/2002 | CA2432364A1 Bax-responsive genes for drug target identification in yeast and fungi |
| 08/22/2002 | CA2432111A1 Jfy1 protein induces rapid apoptosis |
| 08/22/2002 | CA2427741A1 Polynucleotide encoding a novel human potassium channel alpha-subunit, k+alpham1, and variants thereof |
| 08/22/2002 | CA2425732A1 Optimized messenger rna |
| 08/21/2002 | EP1233062A2 Destabilisation of viral quasi-species distributions - avoiding resistance phenomena |
| 08/21/2002 | EP1233059A1 Influenza viruses with enhanced transcriptional and replicational capacities |
| 08/21/2002 | EP1232759A1 Gene transfer-mediated angiogenesis therapy |
| 08/21/2002 | EP1232758A1 Polynucleotide formulated for improved intracellular transfer |
| 08/21/2002 | EP1232284A1 Genomic polymorphism for predicting therapeutic response |
| 08/21/2002 | EP1232276A2 Vectors and transgenes with regulatory elements for gene delivery to the liver |
| 08/21/2002 | EP1232271A2 Methods and means for regulation of gene expression |
| 08/21/2002 | EP1232267A2 Activation of hcv-specific t cells |
| 08/21/2002 | EP1232266A2 Polypeptides and nucleic acids encoding same |
| 08/21/2002 | EP1232264A2 Human fgf-21 gene and gene expression products |
| 08/21/2002 | EP1232263A2 Polypeptides and nucleic acids encoding same |